Terms: = Prostate cancer AND IDH1, IDP, 3417, ENSG00000138413, IDH, PICD, O75874
63 results:
1. Race-specific coregulatory and transcriptomic profiles associated with DNA methylation and androgen receptor in prostate cancer.
Ramakrishnan S; Cortes-Gomez E; Athans SR; Attwood KM; Rosario SR; Kim SJ; Mager DE; Isenhart EG; Hu Q; Wang J; Woloszynska A
Genome Med; 2024 Apr; 16(1):52. PubMed ID: 38566104
[TBL] [Abstract] [Full Text] [Related]
2. APOBEC3C is a novel target for the immune treatment of lower-grade gliomas.
Zhao S; Li Y; Xu J; Shen L
Neurol Res; 2024 Mar; 46(3):227-242. PubMed ID: 38007705
[TBL] [Abstract] [Full Text] [Related]
3. Genomic characterization of idh-mutant astrocytoma progression to grade 4 in the treatment setting.
Rautajoki KJ; Jaatinen S; Hartewig A; Tiihonen AM; Annala M; Salonen I; Valkonen M; Simola V; Vuorinen EM; Kivinen A; Rauhala MJ; Nurminen R; Maass KK; Lahtela SL; Jukkola A; Yli-Harja O; Helén P; Pajtler KW; Ruusuvuori P; Haapasalo J; Zhang W; Haapasalo H; Nykter M
Acta Neuropathol Commun; 2023 Nov; 11(1):176. PubMed ID: 37932833
[TBL] [Abstract] [Full Text] [Related]
4. 68 Ga-PSMA-11 PET/CT Imaging in Brain Gliomas and Its Correlation With Clinicopathological Prognostic Parameters.
Verma P; Singh BK; Sudhan MD; Singh RK; Bagul SD; Chandak AR; Soni BK; Shelly D; Basu S
Clin Nucl Med; 2023 Dec; 48(12):e559-e563. PubMed ID: 37883060
[TBL] [Abstract] [Full Text] [Related]
5. Construction of lncRNA/Pseudogene-miRNA Network Based on In Silico Approaches for Glycolysis Pathway to Identify prostate Adenocarcinoma-Related Potential Biomarkers.
Khorsand M; Mostafavi-Pour Z; Tahmasebi A; Omidvar Kordshouli S; Mousavi P
Appl Biochem Biotechnol; 2024 Apr; 196(4):2332-2355. PubMed ID: 37542606
[TBL] [Abstract] [Full Text] [Related]
6. Isocitrate dehydrogenase 1 sustains a hybrid cytoplasmic-mitochondrial tricarboxylic acid cycle that can be targeted for therapeutic purposes in prostate cancer.
Gonthier K; Weidmann C; Berthiaume L; Jobin C; Lacouture A; Lafront C; Harvey M; Neveu B; Loehr J; Bergeron A; Fradet Y; Lacombe L; Riopel J; Latulippe É; Atallah C; Shum M; Lambert JP; Pouliot F; Pelletier M; Audet-Walsh É
Mol Oncol; 2023 Oct; 17(10):2109-2125. PubMed ID: 37086156
[TBL] [Abstract] [Full Text] [Related]
7. Occurrence of non-central nervous system cancers during postoperative follow-up of patients who underwent surgery for a WHO grade II glioma: implications for therapeutic management.
Duffau H
J Neurooncol; 2023 Mar; 162(1):237-244. PubMed ID: 36913047
[TBL] [Abstract] [Full Text] [Related]
8. Glycyl-tRNA Synthetase (GARS) Expression Is Associated with prostate cancer Progression and Its Inhibition Decreases Migration, and Invasion In Vitro.
Khosh Kish E; Gamallat Y; Choudhry M; Ghosh S; Seyedi S; Bismar TA
Int J Mol Sci; 2023 Feb; 24(5):. PubMed ID: 36901698
[TBL] [Abstract] [Full Text] [Related]
9. Pan-cancer association of DNA repair deficiencies with whole-genome mutational patterns.
Sørensen SG; Shrikhande A; Poulsgaard GA; Christensen MH; Bertl J; Laursen BE; Hoffmann ER; Pedersen JS
Elife; 2023 Mar; 12():. PubMed ID: 36883553
[TBL] [Abstract] [Full Text] [Related]
10. Highly Recurrent idh1 Mutations in prostate cancer With Psammomatous Calcification.
Mehra R; Shah T; Liu CJ; Plouffe KR; Wang X; Mannan R; Cao X; Chinnaiyan AM; Tomlins SA; Udager AM
Mod Pathol; 2023 Jun; 36(6):100146. PubMed ID: 36828361
[TBL] [Abstract] [Full Text] [Related]
11. Determination of TMPRSS2-ERG, SPOP, FOXA1, and idh1 prostate cancer molecular subtypes in Colombian patients and their possible implications for prognosis.
Montero-Ovalle W; Sanabria-Salas MC; Mesa-López de Mesa J; Varela-Ramírez R; Segura-Moreno YY; Sánchez-Villalobos SA; Nuñez-Lemus M; Serrano ML
Cell Biol Int; 2023 May; 47(5):1017-1030. PubMed ID: 36740223
[TBL] [Abstract] [Full Text] [Related]
12. Identification and Validation of TRIM25 as a Glucose Metabolism Regulator in prostate cancer.
Li C; Dou P; Lu X; Guan P; Lin Z; Zhou Y; Lu X; Lin X; Xu G
Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012594
[TBL] [Abstract] [Full Text] [Related]
13. PTPRD and CNTNAP2 as markers of tumor aggressiveness in oligodendrogliomas.
Rautajoki KJ; Jaatinen S; Tiihonen AM; Annala M; Vuorinen EM; Kivinen A; Rauhala MJ; Maass KK; Pajtler KW; Yli-Harja O; Helén P; Haapasalo J; Haapasalo H; Zhang W; Nykter M
Sci Rep; 2022 Aug; 12(1):14083. PubMed ID: 35982066
[TBL] [Abstract] [Full Text] [Related]
14. Whole-exome sequencing analysis of NSCLC reveals the pathogenic missense variants from cancer-associated genes.
Kumar S U; Balasundaram A; Cathryn R H; Varghese RP; R S; R G; Younes S; Zayed H; Doss C GP
Comput Biol Med; 2022 Sep; 148():105701. PubMed ID: 35753820
[TBL] [Abstract] [Full Text] [Related]
15. Proteome profiling of enzalutamide-resistant cell lines and serum analysis identified ALCAM as marker of resistance in castration-resistant prostate cancer.
Csizmarik A; Keresztes D; Nagy N; Bracht T; Sitek B; Witzke K; Puhr M; Tornyi I; Lázár J; Takács L; Kramer G; Sevcenco S; Maj-Hes A; Jurányi Z; Hadaschik B; Nyirády P; Szarvas T
Int J Cancer; 2022 Oct; 151(8):1405-1419. PubMed ID: 35689436
[TBL] [Abstract] [Full Text] [Related]
16. Analysis and Validation of Key Genes Related to Radiosensitivity in prostate cancer.
Huang W; Xu Y
Urol J; 2022 Dec; 20(1):22-28. PubMed ID: 35466393
[TBL] [Abstract] [Full Text] [Related]
17. BRCAness as a Biomarker of Susceptibility to PARP Inhibitors in Glioblastoma Multiforme.
Xavier MA; Rezende F; Titze-de-Almeida R; Cornelissen B
Biomolecules; 2021 Aug; 11(8):. PubMed ID: 34439854
[TBL] [Abstract] [Full Text] [Related]
18. Facile One-Pot Multicomponent Synthesis of Pyrazolo-Thiazole Substituted Pyridines with Potential Anti-Proliferative Activity: Synthesis, In Vitro and In Silico Studies.
El Azab IH; Bakr RB; Elkanzi NAA
Molecules; 2021 May; 26(11):. PubMed ID: 34067399
[TBL] [Abstract] [Full Text] [Related]
19. Structural Analysis of the cl-Par-4 Tumor Suppressor as a Function of Ionic Environment.
Raut KK; Ponniah K; Pascal SM
Biomolecules; 2021 Mar; 11(3):. PubMed ID: 33807852
[TBL] [Abstract] [Full Text] [Related]
20. NCOR1 may be a potential biomarker of a novel molecular subtype of prostate cancer.
Tang L; Zhang L; Liu L; Dong L; Dong Y; Zhu W; Wang H
FEBS Open Bio; 2020 Dec; 10(12):2678-2686. PubMed ID: 33058520
[TBL] [Abstract] [Full Text] [Related]
[Next]
